Smith & Nephew’s (SN) Outperform Rating Reaffirmed at Royal Bank Of Canada

Royal Bank Of Canada reiterated their outperform rating on shares of Smith & Nephew (LON:SN) in a research note issued to investors on Thursday, MarketBeat Ratings reports. They currently have a GBX 1,700 price objective on the stock.

A number of other equities analysts have also weighed in on the company. Deutsche Bank Aktiengesellschaft upped their target price on Smith & Nephew from GBX 1,300 to GBX 1,400 and gave the stock a “hold” rating in a research report on Wednesday, August 6th. Citigroup boosted their price target on shares of Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the company a “buy” rating in a research note on Friday, October 31st. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Smith & Nephew in a research note on Friday, November 7th. Finally, Berenberg Bank lifted their price objective on shares of Smith & Nephew from GBX 1,100 to GBX 1,300 and gave the company a “hold” rating in a report on Thursday, August 7th. Three research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of GBX 1,487.60.

Smith & Nephew Stock Performance

SN stock opened at GBX 1,233.50 on Thursday. The business’s fifty day moving average price is GBX 1,314.42 and its 200 day moving average price is GBX 1,248.30. The firm has a market cap of £13.52 billion, a P/E ratio of 44.41, a P/E/G ratio of 0.46 and a beta of 0.62. The company has a current ratio of 2.51, a quick ratio of 0.84 and a debt-to-equity ratio of 70.22.

Insider Buying and Selling at Smith & Nephew

In related news, insider Deepak Nath sold 1,240 shares of the business’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of GBX 1,257, for a total transaction of £15,586.80. 0.19% of the stock is owned by insiders.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.